Entrepreneur Partner
Vivo Capital, California, United States
Mitchell Mutz, PhD, is an accomplished biotech serial entrepreneur, venture investor, and inventor. He is currently an entrepreneur partner at Vivo Capital, a fund focused on investment opportunities in therapeutics, medical devices, and tools.
Prior to joining Vivo, Mitchell was Senior Investment Director at the Roche Venture Fund, a $500M Swiss corporate venture fund which invests for financial return. His portfolio included Enliven Therapeutics, Fabric Genomics, Good Therapeutics, Jasper Therapeutics (NASDAQ: JSPR), Kumquat Biosciences, lino Biotechnology, Pandion Therapeutics (acquired by Merck), Purigen Biosystems, and Stratos Genomics (acquired by Roche).
Previously, Mitchell was a co-founder, president, chief scientific officer, and board member of Amplyx Pharmaceuticals, Inc., a biotherapeutics company and Stanford University spinout. Mitchell led the company's R&D efforts, team building, as well as financing and in-licensing strategy and helped grow the company from early preclinical discovery to the clinical stage. Amplyx has attracted over $140M in venture financing as well as over $11M in non-dilutive funding from the NIH. Amplyx had a successful Phase 2 clinical trial readout in 2020 and was acquired by Pfizer in 2021.
Mitchell was also on the founding team and the Principal Scientist of Labcyte, a tools company that he helped grow from a garage-based start-up to profitability. Mitchell was responsible for discovering and and developing biotechnology applications for Labcyte's novel acoustic drop ejection technology. Labcyte employs over 250 people worldwide, attracted over $80M in venture financing, and was acquired by Beckman Coulter Life Sciences in 2019.
Mitchell earned a Ph.D. in chemistry from the University of Rochester, a diploma in orchestral studies from the University of London, and a B.A. in chemistry with high honors from Oberlin College. Mitchell is also an inventor on 37 issued patents.
Disclosure information not submitted.
Tuesday, February 8, 2022
11:30 AM – 12:10 PM